Anti-inflammatory Therapy for Recurrent In-stent Restenosis

NCT06090890

Status	RECRUITING
Phase	Phase 4
Sponsor	Fu Wai Hospital, Beijing, China
Enrollment	252 participants

Key Eligibility Criteria

Inclusion (5)

- CAD patients over 18 years old;
- At least one coronary artery lesion meets the RISR criteria: target lesion e 2 ISRs (stenosis of lumen diameter within the stent segment and within 5mm near and far of the stent e 50%);
- Intended intervention treatment for RISR lesions;
- Acceptable for standard secondary prevention drug therapy for coronary heart disease, including dual antiplatelet therapy (DAPT) and statins;
- Willing to participate in the trial and complete follow-up, signing an informed consent form approved by the ethics committee

Exclusion (8)

- The previous interventional treatment situation is unknown;
- The mechanism of intracavitary imaging to clarify ISR is operator-related (poor stent adhesion, incomplete dilation, and stent fracture);
- Clearly diagnose vascular inflammatory diseases or connective tissue diseases (including arteritis, Behcet's disease, systemic lupus erythematosus, etc.) involving the coronary artery;
- Immunosuppressive drugs, including glucocorticoids, have been used in the past 30 days;
- There are contraindications to the use of prednisone or colchicine, including: serious infectious diseases, including active infection, hepatitis B, hepatitis C or AIDS patients; Hematological diseases, such as thrombocytopenia, severe anemia, leukemia, etc; Uncontrolled diabetes; Severe liver and kidney function damage; Active peptic ulcer or gastrointestinal bleeding; Severe osteoporosis (with previous pathological fractures); Inflammatory bowel disease or chronic diarrhea;

... and 3 more (see full listing online)

Locations (4 total)

Beijing Anzhen Hospital, Capital Medical University, Beijing, Beijing Municipality, China
Beijing Friendship Hospital, Beijing, Beijing Municipality, China
Beijing Luhe Hospital, Beijing, Beijing Municipality, China
... and 1 more locations